ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer.
about
Recent developments and best practice in brachytherapy treatment planningFeasibility of vibro-acoustography with a quasi-2D ultrasound array transducer for detection and localizing of permanent prostate brachytherapy seeds: a pilot ex vivo study.Post-treated prostate cancer: normal findings and signs of local relapse on multiparametric magnetic resonance imaging.Radiation safety of receptive anal intercourse with prostate cancer patients treated with low-dose-rate brachytherapy.Radiation therapy in prostate cancer: a risk-adapted strategy.Periprostatic fat measured on computed tomography as a marker for prostate cancer aggressiveness.Low-dose-rate or high-dose-rate brachytherapy in treatment of prostate cancer - between options.Is it necessary to perform week three dosimetric analysis in low-dose-rate brachytherapy for prostate cancer when day 0 dosimetry is done? A quality assurance assessment.Impact of a web-based treatment decision aid for early-stage prostate cancer on shared decision-making and health outcomes: study protocol for a randomized controlled trial.Single blind randomized phase III trial to investigate the benefit of a focal lesion ablative microboost in prostate cancer (FLAME-trial): study protocol for a randomized controlled trial.Iodine seed prostate brachytherapy: an alternative first-line choice for early prostate cancer.Comparison of permanent (125)I seeds implants with two different techniques in 500 cases of prostate cancer.Using prostate-specific antigen screening and nomograms to assess risk and predict outcomes in the management of prostate cancer.Monte Carlo simulation of a realistic anatomical phantom described by triangle meshes: application to prostate brachytherapy imaging.Prostate cancer brachytherapy: guidelines overview.Analysis of monotherapy prostate brachytherapy in patients with prostate cancer. Initial PSA and Gleason are important for recurrence?Follow-up care for men with prostate cancer and the role of primary care: a systematic review of international guidelines.Less-restrictive, patient-specific radiation safety precautions can be safely prescribed after permanent seed implantation.Prostate Cancer Radiation Therapy: What Do Clinicians Have to Know?Brachytherapy in the therapy of prostate cancer - an interesting choicePredictors in the outcome of 125I brachytherapy as monotherapy for prostate cancer.Patterns of outcome and toxicity after salvage prostatectomy, salvage cryosurgery and salvage brachytherapy for prostate cancer recurrences after radiation therapy: a multi-center experience and literature review.AAPM and GEC-ESTRO guidelines for image-guided robotic brachytherapy: report of Task Group 192.Brachytherapy: state-of-the-art radiotherapy in prostate cancer.Challenges in MR-only seed localization for postimplant dosimetry in permanent prostate brachytherapy.Quality indicators and technique for analyzing permanent I-125 prostate seed implants: Seven years postimplant dosimetry evaluation.American Brachytherapy Society Task Group Report: Use of androgen deprivation therapy with prostate brachytherapy-A systematic literature review.Pulse sequence considerations for simulation and postimplant dosimetry of prostate brachytherapy.Tumour and immune cell dynamics explain the PSA bounce after prostate cancer brachytherapyLow dose rate brachytherapy (LDR-BT) as monotherapy for early stage prostate cancer in Italy: practice and outcome analysis in a series of 2237 patients from 11 institutions.A nomogram to predict Gleason sum upgrading of clinically diagnosed localized prostate cancer among Chinese patients.Intra-operative dosimetry of trans-rectal ultrasound guided I prostate implants using C-arm fluoroscopic images.Prospective multi-center dosimetry study of low-dose Iodine-125 prostate brachytherapy performed after transurethral resection.Technical and dosimetric aspects of iodine-125 seed reimplantation in suboptimal prostate implants.Prostate brachytherapy in New South Wales: patterns of care study and impact of caseload on treatment quality.Improved dosimetry in prostate brachytherapy using high resolution contrast enhanced magnetic resonance imaging: a feasibility study.PREDICT: model for prediction of survival in localized prostate cancer.Pre-plan parameters predict post-implant D90 ≥ 140 Gy for (125)I permanent prostate implants.Permanent 125I-seed prostate brachytherapy: early prostate specific antigen value as a predictor of PSA bounce occurrence.Investigation of 90Y-avidin for prostate cancer brachytherapy: a dosimetric model for a phase I-II clinical study.
P2860
Q27027841-CDF6715D-A37E-47FB-A8F8-B9DC03A5B996Q30403949-EBF4D4D5-DDC9-43F7-A1CB-7630F84709A2Q30976248-F3411F8C-5E87-4BB7-9DB5-7BFFBD7710F6Q33918003-5A632D9C-DDC8-462C-9229-C84F930ABF66Q34111590-B7B7F887-0056-45CF-81C2-3E4A4E19DB80Q34255328-F17CAD5C-F885-44A9-969D-FFD1108508B7Q34342191-8DA38BB0-01B7-479D-B8C4-8B6D9F16FF9DQ35582296-E8389AB0-21D4-4F13-B536-09E2853E406FQ35690071-7D644E69-1E36-417D-A0C2-B3DEE239EBBAQ35777339-B3451DB9-0FF1-4DC8-9516-0623DE02A0DBQ35797101-3F994709-583A-4EB8-B876-25E98A4A6F5DQ36276830-26AE2AE1-9E79-452D-9BFB-E0633A7A45DFQ36432832-90D52E7C-6E78-48B7-B8F8-206A5DE8CE64Q36537643-F683A754-B727-4839-B780-C3FF81338D0EQ36555616-2621CDE7-0575-4DB4-94D0-8E774A864C1CQ36575837-7AF1CE1B-38CC-4025-9925-A7607DE4BC17Q37271162-55FEAEA7-A2F1-41EF-B4C9-73EA6166C225Q37284282-8E44894F-98B5-41AF-8D17-408895FA3395Q37578562-C596EBB9-0186-4488-9DBF-DDBD888B3B08Q37601857-06D8EFEF-9967-4848-B74F-1C68A733A51AQ37821905-CE75B393-6C44-449A-92A2-2D3627E2A19FQ38035794-14F9ABF7-0B6C-4825-BFD2-87867413BB69Q38256663-4122FA29-2B7A-491C-B27F-D71D5DC042A4Q38564059-F5ED4735-648F-463B-A4E3-2C3011B5B009Q38646825-1F2B3F3F-3F01-4FAD-B67D-139E4B301E46Q38779301-84DD6063-B4AD-4C03-8EA4-811238BC4E0FQ39006967-3F7345A3-27D7-409C-8CB8-1F7B79AC093EQ39073417-F8387EEB-AB1B-4FE6-9617-E173FBEB8737Q39610086-A5A88A38-095F-415F-8DEE-A2D1938200A9Q39626881-FB62F320-BF82-4938-9418-76B9AE9B4C63Q39753928-23ED241B-4D47-41B3-B94B-4377685603F2Q39965307-A28CCDAC-2981-4C37-8D87-ECEC57888FEBQ40126200-0BA4AAE2-0181-4F8D-B562-F5F7E4BC63A2Q41082788-C30C9050-8F0C-4429-B4EA-10927FA10D6FQ41123703-DBE7EBDF-41C5-4DBA-AB5A-E120A82FE5ECQ41123713-7D412363-7840-4913-8465-9BFB3572BE7BQ41288229-8F0F5994-4C15-4C8C-A918-28A9900E8F06Q41829621-0CD4EC1B-0351-482B-B71E-B7A967F8420CQ41833600-2B43410C-A663-4E61-B98D-065748F95EB0Q44102830-A713A6B7-63E8-438D-8C1E-D7098C11B609
P2860
ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
ESTRO/EAU/EORTC recommendation ...... for localized prostate cancer.
@en
ESTRO/EAU/EORTC recommendation ...... for localized prostate cancer.
@nl
type
label
ESTRO/EAU/EORTC recommendation ...... for localized prostate cancer.
@en
ESTRO/EAU/EORTC recommendation ...... for localized prostate cancer.
@nl
prefLabel
ESTRO/EAU/EORTC recommendation ...... for localized prostate cancer.
@en
ESTRO/EAU/EORTC recommendation ...... for localized prostate cancer.
@nl
P2093
P1476
ESTRO/EAU/EORTC recommendation ...... for localized prostate cancer.
@en
P2093
EORTC Radiotherapy Group
ESTRA/EAU Urological Brachytherapy Group
J Battermann
P Lavagnini
T de Reijke
P304
P356
10.1016/S0167-8140(00)00306-6
P577
2000-12-01T00:00:00Z